INBX
Inhibrx Biosciences, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.37B
P/E Ratio
—
EPS
$-8.39
Beta
3.32
52W High
$155.29
52W Low
$13.97
50-Day MA
$101.69
200-Day MA
$73.42
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Inhibrx Biosciences, Inc.
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla, California.
Fundamentals
| Revenue (TTM) | $1.30M |
| Gross Profit (TTM) | $-100.07M |
| EBITDA | $-120.71M |
| Operating Margin | -9465.00% |
| Return on Equity | -354.70% |
| Return on Assets | -36.10% |
| Revenue/Share (TTM) | $0.08 |
| Book Value | $-1.44 |
| Price-to-Book | 212.28 |
| Price-to-Sales (TTM) | 1055.65 |
| EV/Revenue | 1069.09 |
| EV/EBITDA | 0.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $14.67M |
| Float | $7.86M |
| % Insiders | 23.16% |
| % Institutions | 83.05% |
Historical Volatility
HV 10-Day
56.24%
HV 20-Day
61.36%
HV 30-Day
91.26%
HV 60-Day
110.90%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($277.50 target)
2
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026